Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag regarding possible adverse cardiovascular events derail this promising new drug for osteoporosis?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells
Cardiovascular Diabetology Open Access 02 November 2023
-
NOTUM inhibition increases endocortical bone formation and bone strength
Bone Research Open Access 08 January 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Khosla, S. & Hofbauer, L. C. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/s2213-8587(17)30188-2 (2017).
Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577–589 (2001).
Khosla, S., Westendorf, J. J. & Oursler, M. J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 118, 421–428 (2008).
Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).
McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).
Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).
Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1708322 (2017).
Rosen, C. J. Romosozumab — promising or practice changing? N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMe1711298 (2017).
Tanko, L. B. et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J. Bone. Miner. Res. 20, 1912–1920 (2005).
Gay, A. & Towler, D. A. Wnt signaling in cardiovascular disease: opportunities and challenges. Curr. Opin. Lipidol. 28, 387–396 (2017).
Acknowledgements
The author's work is supported by NIH grants AG004875, AG048792 and AR027065. In addition, the author greatly appreciates the critical review of this article by M. Drake and J. Farr.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Khosla, S. Romosozumab — on track or derailed?. Nat Rev Endocrinol 13, 697–698 (2017). https://doi.org/10.1038/nrendo.2017.136
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.136
This article is cited by
-
Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells
Cardiovascular Diabetology (2023)
-
NOTUM inhibition increases endocortical bone formation and bone strength
Bone Research (2019)
-
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
Nature Reviews Endocrinology (2018)